Specialists from the Radionuclide Sources and Preparations Department of the State Scientific Center - Research Institute of Atomic Reactors (SSC RIAR, part of the Rosatom State Corporation’s Scientific Division) have received a patent for an innovative technology for the production of a radioactive drug based on actinium-225.
Actinium-225 has unique properties that allow it to be used in nuclear medicine, especially in the treatment of oncological diseases. The patented method ensures the high quality of the final product, which is confirmed by a series of technical tests. The use of alpha emitters, including actinium-225, is considered a promising direction in cancer treatment.
Obtaining a patent strengthens the institute's position as one of the four global manufacturers of actinium-225. The new technology confirms the company's status as an innovative leader and makes a significant contribution to the development of Russian science.
The patented method will accelerate the production of actinium-225, increasing the availability of effective radiopharmaceuticals for cancer patients. This opens up new opportunities for nuclear medicine and confirms the high level of Russian scientific developments in the field of radiation technologies.